Expiration date: 12/2026

Composition

1 vial contains 600 IU of thioctic (alpha-lipoic) acid

Packaging

5 vials

Pharmacological action

Berlithion - drug, regulating the exchange of substances. Thioctic (a-lipoic acid), similar in pharmacological properties to the B vitamins, is formed endogenously during the oxidative decarboxylation of a-keto acids and pyruvic acid.

Involved in the regulation of lipid and carbohydrate metabolism, has hepatoprotective, antioxidant and detoxification effect. Improves trophism of neurons.

Testimony

• diabetic polyneuropathy,
  
• alcoholic polyneuropathy.
  

Contraindications

• pregnancy,
  
• lactation (breastfeeding),
  
• hypersensitivity to the drug.
  

Method of application and doses

In severe forms of polyneuropathy at the beginning of treatment the drug is prescribed in/in 300-600 mg (respectively 12 to 24 ml)/day for 2-4 weeks. Further to supportive therapy and prescribed tablets of 300 mg (1 tab.) 1 time/day.

When the/m introduction, the dose administered at one injection site should not exceed 50 mg (2 ml). I/m administration of the drug at high doses should be implemented in the form of multiple injections (2 ml at each injection site).

Side effects

With the rapid on/in the introduction the possible sensation of heaviness in the head and difficulty breathing, which are themselves. 

CNS: in some cases, after the on/in infusion seizures, diplopia.

With the hematopoietic system: in some cases, after the on/in the introduction was observed petechiae, trombotsitopatii.

From the metabolic: hypoglycemia. 

Allergic reactions: when the/in the introduction at the injection site is possible the appearance of hives and the development of eczema, rarely systemic allergic reactions up to anaphylactic shock. Before the drug into possible skin manifestations of allergic reactions.

Local reactions: sometimes - burning pain at the injection site.

Special instructions

The results of clinical studies in recent years have shown a high efficacy of thioctic (a-lipoic) acid for the treatment of diabetes mellitus type 2 with cardiovascular manifestations of diabetic neuropathy. Therapeutic effect of Berlithion in this group of patients may be the result of the impact of the drug on the autonomic nervous system, in particular by improving the speed of wave propagation in visceral parasympathetic and sympathetic fibers.

Use in Pediatrics

Berlithion should not be prescribed to children and adolescents because of the lack of clinical experience with the drug in this category of patients.

Drug interactions

In vitro thioctic (a-lipoic acid) reacts with complexes containing metal ions (e.g., cisplatin). Therefore, when administered simultaneously with cisplatin may reduce the action of Berlithion.

While the use of ethanol and its metabolites can lead to a weakening of the action of Berlithion.

Berlithion enhances the hypoglycemic effect of insulin and oral hypoglycemic agents.

Pharmaceutical interaction

Thioctic (a-lipoic acid) reacts with glucose molecules (including solutions levulose) sparingly soluble complex compounds.

Berlithion incompatible with glucose solutions, ringer solution and solutions, which are known that they react with SH groups or disulfide bridges.

Storage conditions

store in a cool, dry, dark place.